BirchBioMed Inc. has announced Hamilton Health Sciences’ (HHS) Center for Burn Research as the first clinical trial site for their Phase II / III randomized study. Based in Ontario, Canada, the HHS study site will be one of up to 10 sites involved in the research evaluating the naturally based compound, Kynurenic acid (FS2). The objective is to assess FS2 cream efficacy for scar formation in patients with burn injuries that need skin graft surgery. Canfield’s Clinical Imaging Services team configured a compliant and validated solution to provide 3D surface area measurement performed with the patient on-site and high-quality photo documentation to support the subjective rating scale assessments and measure scar healing.